EMA Validates Tryngolza® for Severe Hypertriglyceridemia Treatment | Sobi®
The news coming out of Stockholm today – the European Medicines Agency’s validation of an application to expand the use of Tryngolza (olezarsen) – might seem distant from the daily lives of people in Austin, Texas. But for a growing number of Central Texans facing severely high triglyceride levels, this development represents a potential turning point in managing a condition that significantly elevates their risk of serious health problems. The EMA validation focuses on extending Tryngolza’s application to treat severe hypertriglyceridemia (sHTG), defined as levels exceeding 880 mg/dL, a condition linked to increased risks of acute pancreatitis, heart disease, and even premature mortality.
Understanding Severe Hypertriglyceridemia and the Promise of Tryngolza
Severe hypertriglyceridemia isn’t just about high cholesterol. it’s a distinct metabolic issue. Triglycerides are a type of fat in the blood, and when they accumulate to dangerously high levels, they can lead to a cascade of health complications. The news release highlights that approximately 2 million people in the EU5 countries (which includes Germany, France, Italy, Spain, and the UK) are living with sHTG, with around 700,000 having levels at or above that critical 880 mg/dL threshold. While specific numbers for Austin or even Texas aren’t readily available, the prevalence of obesity and related metabolic disorders in the region suggests a potentially significant population could benefit from new treatment options. Current standard treatments, often involving diet and exercise, don’t always provide sufficient control for those with the most severe cases.
Tryngolza works differently. Developed by Ionis Pharmaceuticals and commercialized by Sobi in Europe, it’s an RNA-targeted therapy. Essentially, it aims to reduce the production of apoC-III, a protein that regulates triglyceride metabolism. By lowering apoC-III levels, Tryngolza helps the body process and clear triglycerides more effectively. The Phase 3 CORE and CORE2 studies, published in the New England Journal of Medicine in 2025, demonstrated a significant reduction in triglyceride levels compared to placebo, and crucially, showed a reduction in the risk of acute pancreatitis – a painful and potentially life-threatening condition. Dr. Lydia Abad-Franch, Head of R&D and Medical Affairs at Sobi, emphasized that Tryngolza is currently the only pharmacological therapy to demonstrate this reduction in pancreatitis risk.
The Local Impact: Austin’s Healthcare Landscape and Cardiovascular Health
Austin’s rapidly growing population and its reputation as a health-conscious city don’t necessarily translate to immunity from metabolic disorders. The city’s vibrant food scene, while a cultural asset, can likewise contribute to dietary challenges. The increasing prevalence of sedentary lifestyles, even amidst outdoor recreational opportunities, plays a role. Local healthcare providers, such as those at the Dell Medical School at the University of Texas at Austin, are actively researching and addressing cardiovascular health issues, and the potential availability of Tryngolza could develop into a valuable tool in their arsenal. St. David’s HealthCare, another major provider in the region, is also focused on preventative cardiology, and a new treatment option for sHTG would align with their goals.
The validation by the EMA is a crucial step, but it doesn’t automatically signify Tryngolza will be available in the United States. The drug is already approved in the US, Canada, and the EU for familial chylomicronemia syndrome (FCS), a rare genetic disorder. This new application specifically targets the broader population with severe hypertriglyceridemia. The FDA will demand to review and approve the expanded indication before it can be prescribed more widely in the US. However, the positive EMA decision often influences the FDA’s review process, potentially accelerating the timeline.
Navigating the Future: Local Resources for Cardiovascular Health in Austin
Given my background in preventative health and wellness, and understanding the potential impact of this news on residents of Austin, here are three types of local professionals you might need to consult if you’re concerned about high triglyceride levels or related cardiovascular risks:
- Board-Certified Cardiologists with Lipidology Expertise: Don’t just look for a cardiologist; seek one specifically trained in lipidology – the study and treatment of lipids (fats) in the blood. Look for physicians affiliated with leading hospitals like Seton Medical Center Austin or those actively involved in research at Dell Med. They should be able to interpret advanced lipid panels and develop personalized treatment plans.
- Registered Dietitians Specializing in Metabolic Disorders: Diet plays a critical role in managing triglyceride levels. A registered dietitian (RD) with experience in metabolic disorders can support you create a sustainable eating plan tailored to your specific needs and preferences. Look for RDs who practice evidence-based nutrition and can provide guidance on reducing saturated and trans fats, increasing fiber intake, and managing carbohydrate consumption.
- Certified Lipid Specialists/Nurse Practitioners: Increasingly, specialized nurse practitioners and physician assistants are focusing on lipid management. These professionals can often provide comprehensive care, including medication management, lifestyle counseling, and ongoing monitoring, under the supervision of a cardiologist. Ensure they are certified in lipidology and have a strong track record of successful patient outcomes.
Ready to find trusted professionals? Browse our complete directory of top-rated healthcare experts in the Austin area today.